2Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997,40:1725.
3Benucci M, Gobbi FL, de1 Rosso A, et al. Disease activity and antinucleosome antibodies in systemic lupus erythematosus[J]. Scand J Rheumatol, 2003,32: 42-45.
4Min DJ,Kim SJ,Pank SH,et al. Anti-nucleosome antibody:significance in lupus patients lacking anti-double-stranded DNA antibody[J]. Clin Exp Rheumatol, 2002,20:13-18.
5Bertsias G, Ioannidis JPA, Boletis J,et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics [J]. Ann Rheum Dis,2008, 67 : 195- 205.
6Ad Hoe Working Group on Steroid-Sparing Criteria in Lupus. Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting [J]. Arthritis Rheum 2004 ;50:3427- 3431.
7Lu F, Tu Y, Peng X, et al. A prospective muhicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis[J]. Lupus,2008,17: 622- 629.
8Zhang FS, N ie YK,Jin XM,et al. The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy [J]. Rheumatol Int,2009,29(11):1331- 1335.
9Austin H. Lupus membranous nephropathy:controlled trial of prednisone,pulse cyclophosphamide and cyclosporine A [J].J Am Soe Nephrol,2004,15:54A.
10Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosis [ J ]. Lupus, 2004,13 : 168-176.
3Wallace D J, Hahn B H. Dubois lupus erythematosus [ M ]. 6th ed. Philad-elphia: Lippincott William & Wilkins, 2001:663-683.
4Karim M Y, Miranda L C, Tench C M, et al. Presenta- tion and prognosis of the shrinking lung syndrome in sys- temic lupus erythematosus [ J ]. Semin Arthritis Rheum, 2002,31 ( 5 ) : 289-298.
